Current status and prospect of screening and treatment of latent multidrug-resistant tuberculosis infection

doi:10.19983/j.issn.2096-8493.20220148

Abstract

Abstract:

Close contacts with multidrug-resistant tuberculosis (MDR-TB) patients have a high risk of MDR-TB infection. Some of them are prone to develop latent MDR-TB infections so that they will become a key population for tuberculosis management and control. At present, the screening and treatment of latent MDR-TB infection are challenging and still unclear. Therefore, we reviewed the epidemic and the evidence of screening, management or prevention in close contact with MDR-TB.

Key words: Tuberculosis, multidrug-resistant, Contact tracing, Diagnosis, Therapeutics

CLC Number:

Chen Qiuqi, Wu Chaoling, Zhang Peize, Deng Guofang. Current status and prospect of screening and treatment of latent multidrug-resistant tuberculosis infection[J]. Journal of Tuberculosis and Lung Disease , 2022, 3(6): 517-520. doi: 10.19983/j.issn.2096-8493.20220148

References 30

[1]	World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization, 2022.
[2]	Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet, 2022, 399(10325):629-655. doi:10.1016/S0140-6736(21)02724-0. doi: 10.1016/S0140-6736(21)02724-0 URL pmid: 35065702
[3]	Bruins WS, van Leth F. Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review. Infect Dis (Lond), 2017, 49(3):161-169. doi:10.1080/23744235.2016.1262059. doi: 10.1080/23744235.2016.1262059 URL
[4]	World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization, 2018.
[5]	Knight GM, McQuaid CF, Dodd PJ, et al. Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling. Lancet Infect Dis, 2019, 19(8): 903-912. doi:10.1016/S1473-3099(19)30307-X. doi: S1473-3099(19)30307-X URL pmid: 31281059
[6]	Kendall EA, Fofana MO, Dowdy DW. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med, 2015, 3(12):963-972. doi:10.1016/S2213-2600(15)00458-0. doi: 10.1016/S2213-2600(15)00458-0 URL pmid: 26597127
[7]	Shah NS, Yuen CM, Heo M, et al. Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis, 2014, 58 (3): 381-391. doi:10.1093/cid/cit643. doi: 10.1093/cid/cit643 URL pmid: 24065336
[8]	Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis, 2016, 16(10):1193-1201. doi:10.1016/S1473-3099(16)30132-3. doi: S1473-3099(16)30132-3 URL pmid: 27342768
[9]	Jenkins HE, Tolman AW, Yuen CM, et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet, 2014, 383(9928):1572-1579. doi:10.1016/S0140-6736(14)60195-1. doi: 10.1016/S0140-6736(14)60195-1 URL pmid: 24671080
[10]	Mehra M, Cossrow N, Kambili C, et al. Assessment of tuberculosis burden in China using a dynamic disease simulation model. Int J Tuberc Lung Dis, 2013, 17(9):1186-1194. doi:10.5588/ijtld.12.0959. doi: 10.5588/ijtld.12.0959 URL pmid: 23827732
[11]	Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Latent tuberculosis infection: a guide for primary health care providers-Diagnosis of latent TB infection. Atlanta: Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, 2020.
[12]	World Health Organization. WHO operational handbook on tuberculosis (Module 1-Prevention): tuberculosis preventive treatment. Geneva: World Health Organization, 2020.
[13]	Li R, Nordio F, Huang CC, et al. Two Clinical Prediction Tools to Improve Tuberculosis Contact Investigation. Clin Infect Dis, 2020, 71(8): e338-e350. doi:10.1093/cid/ciz1221. doi: 10.1093/cid/ciz1221 URL pmid: 31905406
[14]	Saunders MJ, Wingfield T, Tovar MA, et al. A score to predict and stratify risk of tuberculosis in adult contacts of tuberculosis index cases: a prospective derivation and external validation cohort study. Lancet Infect Dis, 2017, 17(11):1190-1199. doi:10.1016/S1473-3099(17)30447-4. doi: S1473-3099(17)30447-4 URL pmid: 28827142
[15]	World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva: World Health Organization, 2015.
[16]	Marks SM, Mase SR, Morris SB. Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis. Clin Infect Dis, 2017, 64(12):1670-1677. doi:10.1093/cid/cix208. doi: 10.1093/cid/cix208 URL pmid: 28329197
[17]	Gupta A, Swindells S, Kim S, et al. Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease. Clin Infect Dis, 2020, 70(3):425-435. doi:10.1093/cid/ciz235. doi: 10.1093/cid/ciz235 URL pmid: 30942853
[18]	World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management background document on the 2019 revision. Geneva: World Health Organization, 2019.
[19]	Bamrah S, Brostrom R, Dorina F, et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009—2012. Int J Tuberc Lung Dis, 2014, 18(8): 912-918. doi:10.5588/ijtld.13.0028. doi: 10.5588/ijtld.13.0028 URL
[20]	World Health Organization. Global tuberculosis report 2015. Geneva: World Health Organization, 2015.
[21]	Holland DP, Sanders GD, Hamilton CD, et al. Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis. PLoS One, 2012, 7(1): e30194. doi:10.1371/journal.pone.0030194. doi: 10.1371/journal.pone.0030194 URL
[22]	Fox GJ, Oxlade O, Menzies D. Fluoroquinolone Therapy for the Prevention of Multidrug-Resistant Tuberculosis in Contacts. A Cost-Effectiveness Analysis. Am J Respir Crit Care Med, 2015, 192(2):229-237. doi:10.1164/rccm.201501-0069OC. doi: 10.1164/rccm.201501-0069OC URL
[23]	Schluger NW. Prevention of Multidrug-Resistant Tuberculosis in Close Contacts. Back to the Future? Am J Respir Crit Care Med, 2020, 202(8):1077-1078. doi:10.1164/rccm.202006-2488ED. doi: 10.1164/rccm.202006-2488ED URL
[24]	Migliori GB, Tiberi S, Zumla A, et al. MDR/XDR-TB mana-gement of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis, 2020, 92S:S15-S25. doi:10.1016/j.ijid.2020.01.042. doi: 10.1016/j.ijid.2020.01.042 URL
[25]	Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med, 2019, 200(10): e93-e142. doi:10.1164/rccm.201909-1874ST. doi: 10.1164/rccm.201909-1874ST URL
[26]	Seddon JA, Schaaf HS, Marais BJ, et al. Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis. Lancet Respir Med, 2018, 6(9):662-664. doi:10.1016/S2213-2600(18)30329-1. doi: 10.1016/S2213-2600(18)30329-1 URL pmid: 30191832
[27]	Gureva T, Turkova A, Yablokova E, et al. Fluoroquinolone preventive therapy for children exposed to MDR-TB. Int J Tuberc Lung Dis, 2022, 26(2):171-173. doi:10.5588/ijtld.21.0443. doi: 10.5588/ijtld.21.0443 URL pmid: 35086631
[28]	Huang CC, Becerra MC, Calderon R, et al. Isoniazid Preventive Therapy in Contacts of Multidrug-Resistant Tuberculosis. Am J Respir Crit Care Med, 2020, 202(8): 1159-1168. doi:10.1164/rccm.201908-1576OC. doi: 10.1164/rccm.201908-1576OC URL
[29]	Moore DA. What can we offer to 3 million MDRTB household contacts in 2016?. BMC Med, 2016, 14: 64. doi:10.1186/s12916-016-0610-x. doi: 10.1186/s12916-016-0610-x URL
[30]	中华人民共和国国家卫生健康委员会办公厅. 结核病预防控制工作技术规范(2020年版). 2020-04-02.